Morgan Stanley shares declined 1.2% in pre-open trading as the firm absorbed the impact of a fresh analyst downgrade and continued uncertainty around blockbuster AI initial public offerings.
Oppenheimer lowered its recommendation on the bank from "Perform" to "Underperform," a move that altered the consensus picture among analysts. Before this action, the stock carried 10 buy ratings, 14 hold ratings and a single sell rating - positioning Oppenheimer's call as an outlier that nevertheless reignited concerns about valuation.
The downgrade adds to pressure that began late last week when reports emerged suggesting OpenAI may postpone its planned initial public offering from the fall of 2026 into 2027. That development hit Morgan Stanley directly, because the bank is listed as one of the lead underwriters on the OpenAI deal. News of the potential delay sent shares down as much as 4.1% during the previous session before the losses were partially recovered.
Compounding the outlook is Morgan Stanley's involvement with Anthropic's intended listing. Any broad slowdown in AI-focused IPO activity therefore represents a tangible near-term revenue risk for the bank, as underwriting and deal fees tied to those transactions make up a component of capital markets income.
Not every sell-side signal was negative. BMO Capital lifted its price target on Morgan Stanley to $240 from $220 and kept an "Outperform" rating, indicating confidence in the underlying fundamentals. Nevertheless, the contrast between that upbeat view and Oppenheimer's downgrade highlights a divide among analysts about near-term growth drivers and valuation.
Market context underscores that the bank's weakness appears company-specific. The broader equity market was strong in the session, with the S&P 500 advancing 1.2% and the Nasdaq rising 2.1%. Morgan Stanley's pre-market retreat therefore stands out as underperformance relative to the wider rally.
At the time of the pre-market move, the stock was trading at $209.11, well below its 52-week high of $230.47. Taken together, the Oppenheimer downgrade and the delayed mega-IPO outlook have renewed investor caution around the shares, particularly given the potential for reduced fee income from postponed or cooled AI listings.
Summary
- Morgan Stanley shares fell 1.2% pre-market after an Oppenheimer downgrade and ongoing uncertainty around AI IPO timing.
- OpenAI's reported consideration of moving its IPO from fall 2026 into 2027, and Morgan Stanley's role as a lead underwriter, create near-term revenue risk.
- BMO Capital raised its price target to $240 and maintained an "Outperform" rating, creating a split among analysts.
Key points
- Analyst action - Oppenheimer downgraded Morgan Stanley from "Perform" to "Underperform," shifting the analyst landscape that previously included 10 buys, 14 holds and one sell.
- AI IPO exposure - The potential delay of OpenAI's IPO and the bank's engagement on Anthropic's listing pose near-term fee risks for investment banking revenue.
- Market context - Broad market gains (S&P 500 +1.2%, Nasdaq +2.1%) suggest the move is company-specific rather than driven by macro weakness.
Risks and uncertainties
- Timing risk for AI listings - A shift of OpenAI's IPO into 2027 would reduce near-term underwriting income tied to that deal, affecting investment banking revenue.
- Underwriting exposure - Morgan Stanley's role as a lead underwriter on AI mega-deals and participation in Anthropic's planned listing mean a slowdown in that market could weigh on fees.